

| Market Applicability | | | | | | | |
|----------------------|----|----|----|----|----|----|----|
| Market | DC | GA | KY | MD | NJ | NY | WA |
| Applicable | X | X | X | X | X | X | NA |

Non-Preferred Epinephrine Injection

| Override(s) | Approval Duration |
|---------------------------------------|-------------------|
| Prior Authorization Quantity Limit | 1 year |

| Medications | Comments | Quantity Limit |
|---|---------------|----------------------------------|
| epinephrine 0.15 mg and 0.3 mg Symjepi (all strengths) | Preferred | May be subject to quantity limit |
| Auvi-Q (all strengths) | Non-Preferred | |

APPROVAL CRITERIA

I. Individual has received the non-preferred agent in the previous year;

OR

II. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one preferred epinephrine injection agent; **AND**

III. Confirmation for the clinical necessity of the non-preferred agents and the same medical reason and clinical benefit are not expected with the preferred agent;

OR

IV. If Auvi-Q is requested, the individual has the following:

A. Visual deficits requiring the need for an auto-injector with audio cues for self-administration; **OR**

B. Hearing deficits requiring the need for an auto-injector with visual cues for self-administration; **OR**

C. Inability to self-administer and there is a need for an auto-injector with audio or visual cues for appropriate administration by a caregiver; **OR**

D. Auvi-Q 0.1 mg is requested and the individual is between 7.5 kg and 15 kg.

| Market Applicability | | | | | | | |
|----------------------|----|----|----|----|----|----|----|
| Market | DC | GA | KY | MD | NJ | NY | WA |
| Applicable | X | X | X | X | X | X | NA |

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.